Encorafenib lgx818

Resistant cell lines were generated through long-term high-dose treatment using increasing concentrations of ENCO+BINI in every passage as described by Szász et al. [12 (link)]. In brief, cells (70% confluence) were switched to drug-containing growth medium and allowed to grow for three months (5% CO₂ at 37 °C). The concentration of the drug combination at the beginning of treatment was 1 nM for each cell line and increased up to 200 nM. To reach the maximum concentration of the drug combination, the time window varied between three and five months. Resistant cells were maintained in complete medium supplemented with a 200 nM inhibitor mixture. Comparisons of the different parameters (cell viability, invasive potential, protein expression, and transcriptome profile) between the sensitive and resistant cells were performed at the same passage number. Encorafenib (LGX818) and binimetinib (MEK162) were obtained from Selleck Chemicals LLC (Houston, TX, USA). Stock solutions were prepared in dimethyl sulfoxide (DMSO) and stored at −20 °C.